Hulk Hogan of WWE fame faced multiple health issues leading up to his death
Although there has been no confirmation of what led to the fatal event, the famed wrestler had allegedly been facing multiple health issues in the months and years before his death.
In an appearance on Jake Paul's "IMPAULSIVE" podcast in Sept. 2024, Hogan admitted that he'd had 25 surgeries in the last 10 years.
Pro Wrestling Icon Hulk Hogan Dead At 71
This included 10 back surgeries, procedures on both shoulders, and knee and hip replacements on both sides.
Hogan called out the difference between today's fighting rings and the dangerous equipment of the 1970s, which he described as a 22-foot ring with "lumps" and "boards sticking up."
Read On The Fox News App
"It was horrible," he said. "The equipment and jumping up and dropping the damn leg for 40 years, when I had the largest arms in the world — I should've been using 'The Sleeper.'"
He added, "I probably should've quit earlier, but I just loved doing it — and the money was just crazy."
Regardless of the physical consequences of his years in the ring, Hogan stated that he has "no regrets."
Dr Marc Siegel: The Health And Times Of Hulk Hogan
In March 2025, TMZ Sports reported that Hogan had undergone neck surgery to relieve pain, which was a "quick turnaround" that required little recovery time, according to a representative.
Earlier this month, Hogan's wife, Sky Daily, squashed rumors on social media that her husband was in a coma following recent surgery.
She noted in an Instagram post that "his heart is strong, and there was never any lack of oxygen or brain damage."
Daily revealed in her post that Hogan had been recovering from a "major four-level anterior cervical discectomy and fusin (ACDF), which is an intense surgery with a long and layered healing process."
She wrote in a post, "If you look it up, you'll see what the last six weeks have involved … not just for his spine, but also for his vocal cords, and the eating/breathing tubes that are clamped over during surgery. We've been in and out of the hospital to support that recovery."
In an op-ed this week for Fox News Digital, Dr. Marc Siegel, Fox News senior medical analyst, shared that while Hogan will not be remembered for his health struggles and surgeries, they certainly were present.
Those included everything from "his admitted steroid use in the 1990s, to multiple knee and hip replacement surgeries, to shoulder and multiple back surgeries, and finally a neck fusion operation which, by many accounts, was followed by a downhill slide in his health, culminating in a fatal cardiac arrest," Siegel wrote.
Ozzy Osbourne's Rare Form Of Parkinson's Sparks Questions About Lifestyle Choices
The physician also pointed out that Hogan came from a group of professional wrestlers who had a "high incidence" of steroid and drug use, suicide and heart disease.
A recent University of East Michigan study said that wrestlers between 45 and 54 years old were nearly three times more likely to die prematurely than those in the general U.S. population.
"And those numbers increased the older the wrestler was," Siegel added. "Many of these men didn't even make it to their 70s."
He added, "Keep in mind the physical strain of having a large, bulky frame being repeatedly slammed, combined with frequent travel and the emotional stresses of being both an athlete and an entertainer."
Click Here To Sign Up For Our Health Newsletter
In 1994, Hogan reportedly admitted under oath — during the trial of then-WWF Chairman Vince McMahon, who'd been charged with steroid distribution — that he had used steroids "for over a decade" before he stopped.
"Hulk Hogan lived in pain for decades, but it didn't keep him from being a continuing role model for many, including in his later years," Siegel said. "He came to embody physical and spiritual vitality, and that is what he will really be remembered for."
Dr. Bradley Serwer, an interventional cardiologist and chief medical officer at VitalSolution in Maryland, told Fox News Digital that without firsthand knowledge of Hogan's medical history, the exact cause of the reported sudden cardiac arrest "remains unknown."
For more Health articles, visit www.foxnews.com/health
"It was reported that he was experiencing good health until he collapsed," Serwer said. "This presentation is quite common for a heart attack with sudden cardiac arrest."
The most prevalent cause of sudden cardiac arrest is a heart attack, or ischemic heart disease, the cardiologist said.
"When a heart attack occurs, the heart muscle is deprived of oxygen, resulting in the death of muscle tissue," the doctor said. "This condition predisposes the heart to abnormal heart rhythms, such as ventricular fibrillation (Vfib)."
Vfib is characterized by "rapid and irregular electrical activity that causes the ventricles [to] quiver and be ineffective," said Serwer.
This results in the heart's inability to pump blood to the body, leading to a rapid death.
Cardiac arrests that occur outside a hospital have a "significantly low" survival rate of about 10%, according to Serwer.
For those who receive cardiac arrest response, such as CPR and defibrillation, survival increases by up to 40%.Original article source: Hulk Hogan of WWE fame faced multiple health issues leading up to his death
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Medscape
15 minutes ago
- Medscape
Ovarian Cancer Risk Rises Soon After IBS Diagnosis
TOPLINE: Women with a new diagnosis of irritable bowel syndrome (IBS) have a significantly higher risk for ovarian cancer at 3 months and 6 months post-diagnosis, but this risk is no longer elevated beyond 8 months. METHODOLOGY: Ovarian cancer often presents with nonspecific symptoms overlapping those of IBS. The frequency of misdiagnosis remains unknown, and not all IBS guidelines recommend screening for ovarian cancer. Researchers conducted a retrospective cohort study using US administrative claims data to compare ovarian cancer incidence in adult women with and without a new IBS diagnosis. Diagnostic codes were used to identify cases of IBS and ovarian cancer. TAKEAWAY: The cohort comprised 9804 women with IBS and 79,804 women without IBS, identified between January 2017 and December 2020. Women with IBS had a significantly higher risk for ovarian cancer at 3 months (hazard ratio [HR], 1.71; P = .02) and 6 months (HR, 1.43; P = .02), but not beyond 8 months post-diagnosis. Women with both IBS and endometriosis had an even greater risk for ovarian cancer at 3 months (HR, 4.20; P = .01), 6 months (HR, 3.52; P = .01), and after 1 year (HR, 2.67; P = .04). Increasing age was significantly associated with higher ovarian cancer incidence only in women younger than 50 years (HR, 1.07; P < .01), regardless of IBS status. IN PRACTICE: 'Identifying patient-specific risk factors, such as chronic pelvic pain or endometriosis, could help develop tailored risk profiles and improve the approach to personalized care in women with IBS-type symptoms,' the authors wrote. SOURCE: This study was led by Andrea Shin, Vatche and Tamar Manoukian Division of Digestive Diseases, University of California, Los Angeles. It was published online in Alimentary Pharmacology & Therapeutics. LIMITATIONS: The use of diagnostic codes for identifying IBS may have led to misclassification or reflected symptoms rather than confirmed and validated diagnosis. DISCLOSURES: This study received support from the National Institutes of Health. Some authors reported serving as consultants, advisors, and/or receiving research support from pharmaceutical and healthcare companies; one author reported having stock options. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.


Medscape
15 minutes ago
- Medscape
Benzene in Acne Products: What to Know Now
When an independent laboratory filed a citizen's petition in March 2024, urging the FDA to recall and suspend the sale of acne products containing benzoyl peroxide after finding what it termed unacceptably high levels of benzene in acne products it tested, it ignited a range of reactions in the medical community and consumers. Responses ranged from fear to indifference, with even some dermatologists passing off the request as nonsense. However, concerns about the potential for benzoyl peroxide-containing acne products to break down into benzene, a known human carcinogen, have been ongoing. In recent months, as research has accumulated, so has a clearer picture of the risk. The FDA has taken action, although some contend the agency has not done enough, and experts involved are better focused — and sometimes in closer agreement — on how to move forward to increase safety for the products, considered one of the most effective topical acne treatments and the only effective remedy for many patients. Medscape Medical News reached out to John S. Barbieri, MD, MBA, assistant professor of dermatology at Harvard Medical School and director of the Advanced Acne Therapeutics Clinic at Brigham and Women's Hospital, both in Boston, and David Light, president and co-founder of Valisure, the independent laboratory in New Haven, Connecticut, that filed the petition, asking for an update of what they've found out in recent months (they both have published research recently), what they believe needs to be done moving forward, and their advice on how clinicians should be talking to their patients about the products. 'Right now, to me, it's a nonissue clinically,' said Barbieri, who has researched and written about the issue extensively. 'I don't worry about this in my day-to-day practice.' However, he's adamant that more needs to be done to maximize the safety of the products, that patients need to be educated about precautions they can take, and that manufacturers need to focus on getting the benzene levels in their products to what he and others say is achievable — zero. Product Heterogeneity Researchers have found a wide range of levels of benzene in products. That's good news, so to speak, in regard to fixing the problem. As Barbieri and Christopher Bunick, MD, PhD, associate professor of dermatology at Yale University School of Medicine, New Haven, Connecticut, wrote in a recent Viewpoint in JAMA Dermatology, 'there has been considerable heterogeneity observed between brands and product lines, suggesting opportunities to improve formulation, production, and distribution practices to maximize the safety of benzoyl peroxide-containing products.' The range of benzene found, for instance, in the Valisure analysis leading to the citizen's petition was sometimes over 800 times the FDA's conditional limit of 2 parts per million. The JAMA paper also cites a study, published in May 2025, by Bunick, Light, and others, finding that cold storage may reduce benzene formation, and a study co-authored by Barbieri, which found that leave-on benzoyl peroxide products contained lower concentrations of benzene, possibly because they are often manufactured in smaller batches than washes 'and thus may cool more quickly,' they wrote. Recent Recalls In March 2025, the FDA alerted the public and industry to the results of its testing of 95 acne products with benzoyl peroxide for possible benzene contamination, following the receipt of the Valisure test results. As a result of the FDA alert, six companies voluntarily recalled some of their products, and another company voluntarily recalled its product after its own testing. FDA Input? Under nonbinding FDA guidance issued in December 2023, benzene levels in products using carbomers (thickeners) should not exceed 2 parts per million. Medscape Medical News reached out to the FDA, asking if the agency had any other information pertaining to developments in the manufacturing of benzoyl peroxide acne products. A spokesperson referred only to the March 2025 information about recalls and its finding that more than 90% of the benzoyl peroxide acne products it tested had undetectable or very low levels of benzene. Manufacturers' Mission Manufacturers need to do more, Light and Barbieri agreed, to monitor benzene levels and reduce them. 'I'm quite supportive of the paper they wrote,' Light told Medscape Medical News , referring to the JAMA update co-authored by Barbieri and Bunick. 'I appreciate their push on the manufacturers' side,' a stance Light has taken from the start. Information on exactly what the product manufacturers are doing, even after the March recalls and the FDA testing, is scarce, Light and Barbieri agreed. (Light's analyses have previously been the target of some criticism, contending he is mostly interested in winning lawsuits against companies and boosting profits. He has filed patents related to, among other areas, the prevention of the formation of impurities, including benzene, in drug products such as benzoyl peroxide-containing products. In response, Light said his goals have always been focused on public health and consumer protection. 'Our analyses have not only been rigorously reviewed through the peer-review process in multiple journals,' he said, 'but each of our five FDA Citizen Petitions on benzene contamination in major consumer product categories has been followed by testing and validation by regulators and companies that confirmed unacceptably high levels of benzene and initiated recalls.') The Consumer Health Products Association, a trade group that many of the benzoyl peroxide product manufacturers belong to, posted the following statement on its site after the citizen's petition was filed last year: 'Benzene is not intentionally added to any consumer product, and it is important that proper quality control measures are in place to both detect impurities and reduce potential contamination during the manufacturing process.' But it offered no more specific information about individual manufacturers' procedures or attempts at improvements. Beyond quality control measures, manufacturers must pay attention to shipping and distribution, which can affect benzene levels as temperatures rise, Barbieri said. 'Consumer confidence is really important here,' he added. Manufacturers should also transparently share their benzene data, Barbieri and Light agreed. Besides acne products, according to the FDA, hand sanitizers, aerosol antiperspirants, and sunscreen sprays have been recalled because of benzene concerns. Empowering Patients Meanwhile, clinicians can advise patients to take a number of steps to minimize the risk for benzene exposure, according to Barbieri and Light. Discarding expired products or those that have been exposed to high temperatures — such as being left in a hot car — is one recommendation. Replacing products every 10-12 weeks is also probably wise, Barbieri said, but he concedes that more data is needed about the stability of the products at room temperature. Whether refrigerating the products is better than keeping them at room temperature hasn't been fully researched, he noted. Lowering the temperature does help with benzene formation, Light said. In his studies, he found that a single acne product incubated at 158 °C, similar to a hot car, released benzene at concentrations about 1270 times higher than the US Environmental Protection Agency threshold for cancer risk via long-term inhalation. He also cautions against storing the products in the bathroom medicine cabinet because of the higher temperatures. In addition, consumers shouldn't rely on 'best products' lists based on analyses of benzene levels, Barbieri told Medscape Medical News , because the same product could have been purchased in different ways — such as picking it up from the store directly or ordering it online and then having it sit on a hot doorstep for hours. Be cautious using online retailers and pharmacies, he said, for those reasons — the products could have had potentially higher temperature exposure during shipping. Ultraviolet exposure is similar to heat in its effects, Light pointed out. Barbieri said those who use leave-on products should consider sun protection, which, he added, is a useful general recommendation for acne management in general. Looking Forward: Getting to Zero While progress has been made, and awareness of the risks has increased, there's work to be done, experts agreed. 'It's still an important and relevant issue,' Barbieri said. 'We want to be doing as much as we can to mitigate the risk as much as possible. Even if the risk is 0.00001, if we can make it zero, we should make it zero.' Barbieri and Bunick have reported no relevant disclosures. Light has filed patents related to the prevention of the formation of impurities, including benzene, in drug products, such as benzoyl peroxide products. The Journal of Investigative Dermatology study published in May 2025 was funded by Valisure.


Forbes
16 minutes ago
- Forbes
The World's Best Whiskey—According To The 2025 New Orleans Spirits Competition
A marriage of Scotch and American whiskey-making traditions, Lineage took home the top prize at the ... More 4th annual New Orleans Spirits Competition All the talk in the spirits world last week was reserved for Tales of the Cocktail, the industry's largest annual conference. But since 2022, the gathering – which takes place every July – has also played host to a lesser known judging event: The New Orleans Spirit Competition. A late arrival to the increasingly dense booze-award-industrial-complex, NOSC is looking to make up for lost time by coming out of the gates with an impressive array of professional palates. It helps, no doubt, that many of them are already in town for Tales. The competition also professes to stand out thanks to its unique evaluation format. The entries are judged, as described on its website, thusly: To be clear, the audience does not get an actual vote in the process. But they do enjoy a place in the room and are afforded an opportunity to be a part of the conversation. As such, it's a slightly more democratized process than anything else you'll see in the industry. And, as with any truly independent competition, each spirit is tasted in the blind. Ultimately, hundreds of awards are doled out ranging from Best of Category down through Double Gold, Gold, Silver and Bronze. There's also a separate evaluation for Packaging Excellence. But what we care most about is how it all distills down in the best of the best distinctions. For that there are 11 separate 'Spirits of the Year." There can be only one for all the major liquor categories plus RTD, No & Low Elixir, and Syrups & Mixers. Today we're taking a closer look at what those panelists deemed the best whiskey of the year for 2025: Balcones Lineage, an American Single Malt distilled and aged in Waco, Texas. The unique 94-proof liquid marries whiskey making traditions typical to both the US and Scotland. To wit, it's made from a combination of Scottish and Texas-grown barley, which is then matured in refill and new oak barrels. The best of both worlds; Old and New. In the pour, this hybridization results in a sweeter, fruitier nose – raspberry, banana and apricot steal top-notes from the underlying malt. There is a dryness to the initial sip; cedar and sarsaparilla, opening up to reveal cinnamon spice in the finish. A prolonged breadiness stays with the back of the tongue long after it has gone down. All in all this is a fantastically approachable dram, particularly from this distillery – a craft darling which was purchased by Diageo in 2022. Balcones often brings to bottle higher-proof offerings that can be challenging to the whiskey novice. With Lineage, it has managed to walk that fine line, delivering something that satisfies newcomers and advanced sippers, alike. And it does so at the crowd-pleasing price of $40 a bottle. To take home the top prize, Lineage bested some big names from far more prominent genres of whiskey, including the Bourbon and Scotch categories that helped informed its creation – categories with hundreds of years of history. American Single Malt, by comparison, was only formally recognized as a style at the beginning of 2025. Perhaps laudable recognition such as this can help lift its stature on the international stage. Either way, it arrives at a pivotal time for American spirits as a whole. According to the most recent economic report from DISCUS, exports of such just reached a record high of $2.4 billion. And as of this weekend, the US and the European Union appear to be on the precipice of a new trade agreement which would keep those exports shipping out, tariff free. 'We are optimistic that in the days ahead this positive meeting and agreement will lead to a return to zero-for-zero tariffs for U.S. and EU spirits products,' says DISCUS president and CEO Chris Swonger. 'This will benefit not only our nation's distillers, but also the American workers and farmers who support them from grain to glass.' It'll also benefit European connoisseurs eager for their first sampling of American Single Malt. And for that, as the judges in New Orleans have made clear, Balcones Lineage is a sensible starting point. The whiskeys from Balcones distillery feel bold, clean and distinctly American. (Bill Hogan/Chicago ... More Tribune/Tribune News Service via Getty Images)